Search

Objective: To provide clinical reference for the prevention and treatment of HIV positive bladder cancer by comparing and analyzing the basic information, laboratory examination, treatment and follow-up of HIV positive and non-HIV infected bladder cancer patients. Methods: This study collected 57 bladder cancer patients with complete data who were admitted to Beijing Ditan Hospital and Beijing You 'an Hospital from 2013 to 2021, including 14 cases in the HIV positive group and 43 cases in the HIV negative group. A retrospective analysis was conducted on the HIV infection route of HIV positive patients and whether antiviral treatment was regular. The viral load and the number of CD4+T lymphocytes before surgery were compared. The preoperative laboratory examination, pathological grade, treatment methods, 3-month recurrence and long-term follow-up of bladder cancer patients in the two groups were compared. Results: In this study, the average age of onset in the HIV positive group was (48.93±13.83) years old, while the average age of onset in the non-HIV group was (62.05±13.38) years old, and the difference was statistically significant (P0.05), but there were statistically significant differences in red blood cell values between the two groups (P0.05). The median long-term follow-up was 40 months (8-78 months). The survival rate of the two groups was HIV VS non-HIV (71.42% VS 93.02%) (P>0.05). Conclusions: The clinical characteristics of HIV-positive bladder cancer patients are similar to that of the general population, and HIV positive bladder cancer patients also follow the guidelines for the general population in terms of treatment measures. The early age of HIV positive bladder cancer patients remains to be further studied.

Purpose: This study was intended to determine whether differences existed between bladder cancers in HIV-infected patients compared to those in the general population. Patients and methods: In this study, 14 patients with HIV infection were found also to have bladder cancer, treated in Beijing Ditan Hospital and Beijing You 'an Hospital from 2013 to 2021. The retrospective study parameters analyzed included HIV infection route, regular treatment, viral load and number of CD4+T lymphocytes prior to surgery, and preoperative laboratory examination. Details specific to bladder cancer included pathological stage and grade, treatment, recurrence at 3 months and longer-term follow-up. Results: The study comprised 13 males (93%) and 1 female (7%), with a median age of 50.5 years, of whom only 9 patients received regular antiretroviral therapy after HIV infection. The median value of CD4+T lymphocytes detected before surgery was 368 cells/μL (range: 147cells/μL-759cells /μL). Other preoperative laboratory results were as follows (median counts): WBC, 6.165×109 /L; erythrocytes, 4.16×1012 /L; hemoglobin, 214.5 g/L; platelets, 143×109 /L; creatinine, 70.85μmol/L; and serum albumin, 41.5 g/L. All patients were treated surgically, 11 of whom had non-muscle invading bladder cancer that underwent localized tumor resection (plus epirubicin bladder infusion) , and the remaining 3 patients had tumor invasion of the muscle that required radical resection (plus postoperative chemotherapy). The cancers were all urothelial, 5 high-grade and 9 low-grade histologically. At three months postoperatively, 3 cases had recurred and were re-excised, 7 had no evidence of recurrence, and 4 had not undergone reevaluation. On subsequent longer-term follow-up (median, 40 months), 2 patients had died[1] of unrelated causes, 10 were alive[2] including 1 with liver metastasis, and 2 were lost to follow-up.Conclusions: The clinical characteristics of HIV-positive patients with bladder cancer were similar to those of the general population with the exception of a significant earlier onset of disease. The type and stages of the bladder cancer, treatment, and outcomes of these patients were also similar to the general population. However, the cause of earlier onset of bladder cancer in HIV positive patients remains to be further elucidated.